Who makes Bimatoprost 0.03%, Travoprost 0.004%?

Bimatoprost 0.03%, Travoprost 0.004% is developed by Innovative Medical.

What development phase is Bimatoprost 0.03%, Travoprost 0.004% in?

Bimatoprost 0.03%, Travoprost 0.004% is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Bimatoprost 0.03%, Travoprost 0.004%

Innovative Medical · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Bimatoprost 0.03%, Travoprost 0.004%
Sponsor	Innovative Medical
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% (PHASE4)
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues (PHASE4)
Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
Safety and Efficacy of Changing to DuoTrav From Prior Therapy (PHASE4)
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye (PHASE4)
Efficacy of Changing to DUOTRAV® From Prior Therapy (PHASE4)
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bimatoprost 0.03%, Travoprost 0.004% CI brief — competitive landscape report
Bimatoprost 0.03%, Travoprost 0.004% updates RSS · CI watch RSS
Innovative Medical portfolio CI